Lack of evidence to support the association of a single IL28B genotype SNP rs12979860 with the HTLV-1 clinical outcomes and proviral load

BMC Infectious Diseases

Ester Cerdeira Sabino⁴  Esper Georges Kallas¹  Aluisio C Segurado⁴  Fabio Eudes Leal¹  Rodrigo Pessôa³  Ana Carolina Soares de Oliveira³  Antonio Charlys da Costa³  Juliana Pereira⁵  Youko Nukui⁵  Sabri Saeed Sanabani² 

[1] Division of Clinical Immunology and Allergy, University of Sao Paulo Medical School, São Paulo, Brazil;São Paulo Inistitute of Tropical Medicine, São Paulo, Brazil;Clinical Laboratory, Department of Pathology, LIM 03, Hospital das Clínicas (HC), School of Medicine, University of São Paulo, São Paulo, Brazil;Deparment of Infectious Diseases, School of Medicine, University of Sao Paulo, São Paulo, Brazil;Department of Hematology, University of São Paulo, São Paulo, Brazil

关键词: Proviral load;    HAM/TSP;    ILB 28 polymorphisms;    HTLV-1;   

Others  :  1158651
DOI  :  10.1186/1471-2334-12-374

 received in 2012-07-10, accepted in 2012-12-20,  发布年份 2012

【 摘 要 】

Background

The Interleukin 28B (IL28B) rs12979860 polymorphisms was recently reported to be associated with the human T-cell leukemia virus type 1 (HTLV-1) proviral load (PvL) and the development of the HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

Methods

In an attempt to examine this hypothesis, we assessed the association of the rs12979860 genotypes with HTLV-1 PvL levels and clinical status in 112 unrelated Brazilian subjects (81 HTLV-1 asymptomatic carriers, 24 individuals with HAM/TSP and 7 with Adult T cell Leukemia/Lymphoma (ATLL)).

Results

All 112 samples were successfully genotyped and their PvLs compared. Neither the homozygote TT nor the heterozygote CT mutations nor the combination genotypes (TT/CT) were associated with a greater PvL. We also observed no significant difference in allele distribution between asymptomatic carriers and patients with HTLV-1 associated HAM/TSP.

Conclusions

Our study failed to support the previously reported positive association between the IL28B rs12979860 polymorphisms and an increased risk of developing HAM/TSP in the Brazilian population.

【 授权许可】

   
2012 Sanabani et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC: Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 1980, 77(12):7415-7419.
• [2]Edlich RF, Arnette JA, Williams FM: Global epidemic of human T-cell lymphotropic virus type-I (HTLV-I). J Emerg Med 2000, 18(1):109-119.
• [3]Matsuoka M: Human T-cell leukemia virus type I and adult T-cell leukemia. Oncogene 2003, 22(33):5131-5140.
• [4]Verdonck K, Gonzalez E, Van Dooren S, Vandamme AM, Vanham G, Gotuzzo E: Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis 2007, 7(4):266-281.
• [5]Franchini G, Ambinder RF, Barry M: Viral Disease in Hematology. Hematology (Am Soc Hematol Educ Program) 2000, 409-423.
• [6]Murphy EL, Hanchard B, Figueroa JP, Gibbs WN, Lofters WS, Campbell M, Goedert JJ, Blattner WA: Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. Int J Cancer 1989, 43(2):250-253.
• [7]Yamaguchi K, Watanabe T: Human T lymphotropic virus type-I and adult T-cell leukemia in Japan. Int J Hematol 2002, 76(Suppl 2):240-245.
• [8]Matsuoka M, Jeang KT: Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 2007, 7(4):270-280.
• [9]Yoshida M, Seiki M, Yamaguchi K, Takatsuki K: Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci U S A 1984, 81(8):2534-2537.
• [10]Takeda S, Maeda M, Morikawa S, Taniguchi Y, Yasunaga J, Nosaka K, Tanaka Y, Matsuoka M: Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells. Int J Cancer 2004, 109(4):559-567.
• [11]Mesnard JM, Barbeau B, Devaux C: HBZ, a new important player in the mystery of adult T-cell leukemia. Blood 2006, 108(13):3979-3982.
• [12]Koziel MJ: Cytokines in viral hepatitis. Semin Liver Dis 1999, 19(2):157-169.
• [13]Tsukasaki K, Miller CW, Kubota T, Takeuchi S, Fujimoto T, Ikeda S, Tomonaga M, Koeffler HP: Tumor necrosis factor alpha polymorphism associated with increased susceptibility to development of adult T-cell leukemia/lymphoma in human T-lymphotropic virus type 1 carriers. Cancer Res 2001, 61(9):3770-3774.
• [14]Jeffery KJ, Usuku K, Hall SE, Matsumoto W, Taylor GP, Procter J, Bunce M, Ogg GS, Welsh KI, Weber JN, et al.: HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci U S A 1999, 96(7):3848-3853.
• [15]Jeffery KJ, Siddiqui AA, Bunce M, Lloyd AL, Vine AM, Witkover AD, Izumo S, Usuku K, Welsh KI, Osame M, et al.: The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection. J Immunol 2000, 165(12):7278-7284.
• [16]Nishimura Y, Okubo R, Minato S, Itoyama Y, Goto I, Mori M, Hirayama K, Sasazuki T: A possible association between HLA and HTLV-I-associated myelopathy (HAM) in Japanese. Tissue Antigens 1991, 37(5):230-231.
• [17]Nishimura M, Maeda M, Matsuoka M, Mine H, Saji H, Matsui M, Kuroda Y, Kawakami H, Uchiyama T: Tumor necrosis factor, tumor necrosis factor receptors type 1 and 2, lymphotoxin-alpha, and HLA-DRB1 gene polymorphisms in human T-cell lymphotropic virus type I associated myelopathy. Hum Immunol 2000, 61(12):1262-1269.
• [18]Nishimura M, Matsuoka M, Maeda M, Mizuta I, Mita S, Uchino M, Matsui M, Kuroda Y, Kawakami H, Kaji R, et al.: Association between interleukin-6 gene polymorphism and human T-cell leukemia virus type I associated myelopathy. Hum Immunol 2002, 63(8):696-700.
• [19]Sabouri AH, Saito M, Lloyd AL, Vine AM, Witkover AW, Furukawa Y, Izumo S, Arimura K, Marshall SE, Usuku K, et al.: Polymorphism in the interleukin-10 promoter affects both provirus load and the risk of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. J Infect Dis 2004, 190(7):1279-1285.
• [20]Gadelha SR, Junior Alcantara LC, Costa GC, Acosta AX, Rios D, Kashima S, Covas DT, Galvao-Castro B: Correlation between polymorphisms at interleukin-6 but not at interleukin-10 promoter and the risk of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis in Brazilian individuals. J Med Virol 2008, 80(12)):2141-2146.
• [21]Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, et al.: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461(7262):399-401.
• [22]Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, et al.: IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009, 41(10):1100-1104.
• [23]Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, et al.: Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009, 41(10):1105-1109.
• [24]Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, et al.: Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010, 139(1):120-129. e118
• [25]Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, et al.: Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010, 138(4):1338-1345. 1345 e1331-1337
• [26]Rallon NI, Naggie S, Benito JM, Medrano J, Restrepo C, Goldstein D, Shianna KV, Vispo E, Thompson A, McHutchison J, et al.: Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010, 24(8):F23-F29.
• [27]Nattermann J, Vogel M, Nischalke HD, Danta M, Mauss S, Stellbrink HJ, Baumgarten A, Mayr C, Bruno R, Tural C, et al.: Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C. J Infect Dis 2011, 203(5):595-601.
• [28]Trevino A, Lopez M, Vispo E, Aguilera A, Ramos JM, Benito R, Roc L, Eiros JM, de Mendoza C, Soriano V: Development of Tropical Spastic Paraparesis in Human T-Lymphotropic Virus Type 1 Carriers Is Influenced by Interleukin 28B Gene Polymorphisms. Clin Infect Dis 2012, 55(1):e1-e4.
• [29]Osame: Review of WHO Kagoshima Meeting and diagnostic guidelines for HAM/TSP. In Human Retrovirology: HTLV. Edited by Blattner W. New York: Raven; 1990:191-197.
• [30]Neto WK, Da-Costa AC, de Oliveira AC, Martinez VP, Nukui Y, Sabino EC, Sanabani SS: Correlation between LTR point mutations and proviral load levels among human T cell lymphotropic virus type 1 (HTLV-1) asymptomatic carriers. Virol J 2011, 8:535. BioMed Central Full Text
• [31]Scagnolari C, Midulla F, Riva E, Monteleone K, Solimini A, Bonci E, Cangiano G, Papoff P, Moretti C, Pierangeli A, et al.: Evaluation of interleukin 28B single nucleotide polymorphisms in infants suffering from bronchiolitis. Virus Res 2012, 165(2):236-240.
• [32]Nagai M, Usuku K, Matsumoto W, Kodama D, Takenouchi N, Moritoyo T, Hashiguchi S, Ichinose M, Bangham CR, Izumo S, et al.: Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol 1998, 4(6):586-593.
• [33]Iwanaga M, Watanabe T, Utsunomiya A, Okayama A, Uchimaru K, Koh KR, Ogata M, Kikuchi H, Sagara Y, Uozumi K, et al.: Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood 2010, 116(8):1211-1219.
• [34]Gabet AS, Mortreux F, Talarmin A, Plumelle Y, Leclercq I, Leroy A, Gessain A, Clity E, Joubert M, Wattel E: High circulating proviral load with oligoclonal expansion of HTLV-1 bearing T cells in HTLV-1 carriers with strongyloidiasis. Oncogene 2000, 19(43):4954-4960.
• [35]Kamihira S, Dateki N, Sugahara K, Hayashi T, Harasawa H, Minami S, Hirakata Y, Yamada Y: Significance of HTLV-1 proviral load quantification by real-time PCR as a surrogate marker for HTLV-1-infected cell count. Clin Lab Haematol 2003, 25(2):111-117.
• [36]Manns A, Miley WJ, Wilks RJ, Morgan OS, Hanchard B, Wharfe G, Cranston B, Maloney E, Welles SL, Blattner WA, et al.: Quantitative proviral DNA and antibody levels in the natural history of HTLV-I infection. J Infect Dis 1999, 180(5):1487-1493.
• [37]Jonsson JR, Purdie DM, Clouston AD, Powell EE: Recognition of genetic factors influencing the progression of hepatitis C: potential for personalized therapy. Mol Diagn Ther 2008, 12(4):209-218.
• [38]Rallon NI, Restrepo C, Naggie S, Lopez M, Del Romero J, Goldstein D, McHutchison J, Soriano V, Benito JM: Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline. AIDS 2011, 25(2):269-271.
• [39]Martin MP, Qi Y, Goedert JJ, Hussain SK, Kirk GD, Hoots WK, Buchbinder S, Carrington M, Thio CL: IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis 2010, 202(11):1749-1753.
• [40]Kamihira S, Usui T, Ichikawa T, Uno N, Morinaga Y, Mori S, Nagai K, Sasaki D, Hasegawa H, Yanagihara K, et al.: Paradoxical expression of IL-28B mRNA in peripheral blood in human T-cell leukemia virus type-1 mono-infection and co-infection with hepatitis C virus. Virol J 2012, 9:40. BioMed Central Full Text